Related references
Note: Only part of the references are listed.Effectiveness and Cost-Effectiveness of Human Papillomavirus Vaccination Through Age 45 Years in the United States
Jean-Francois Laprise et al.
ANNALS OF INTERNAL MEDICINE (2020)
Estimating the Natural History of Cervical Carcinogenesis Using Simulation Models: A CISNET Comparative Analysis
Emily A. Burger et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2020)
Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices
Elissa Meites et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2019)
Declines in Anogenital Warts Among Age Groups Most Likely to Be Impacted by Human Papillomavirus Vaccination, United States, 2006-2014
Elaine W. Flagg et al.
AMERICAN JOURNAL OF PUBLIC HEALTH (2018)
Human papillomavirus vaccination in commercially-insured vaccine-eligible males and females, United States, 2007-2014
Julia W. Gargano et al.
VACCINE (2018)
Cost-effectiveness of nonavalent HPV vaccination among males aged 22 through 26 years in the United States
Harrell W. Chesson et al.
VACCINE (2018)
Human papillomavirus vaccination coverage among females and males, National Health and Nutrition Examination Survey, United States, 2007-2016
Rayleen M. Lewis et al.
VACCINE (2018)
Comparison of anal HPV natural history among men by country of residence: Brazil, Mexico, and the United States
Staci L. Sudenga et al.
JOURNAL OF INFECTION (2017)
Modeling of US Human Papillomavirus (HPV) Seroprevalence by Age and Sexual Behavior Indicates an Increasing Trend of HPV Infection Following the Sexual Revolution
Marc D. Ryser et al.
JOURNAL OF INFECTIOUS DISEASES (2017)
Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial
Warner K. Huh et al.
LANCET (2017)
Changes in the Distribution of Sex Partners in the United States: 2002 to 2011-2013
Christopher R. Harper et al.
SEXUALLY TRANSMITTED DISEASES (2017)
Seroprevalence of 9 Human Papillomavirus Types in the United States, 2005-2006
Gui Liu et al.
JOURNAL OF INFECTIOUS DISEASES (2016)
Progression of HPV infection to detectable cervical lesions or clearance in adult women: Analysis of the control arm of the VIVIANE study
S. Rachel Skinner et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
Accuracy of Death Certificates and Assessment of Factors for Misclassification of Underlying Cause of Death
Makiko Naka Mieno et al.
JOURNAL OF EPIDEMIOLOGY (2016)
Incident Detection of High-Risk Human Papillomavirus Infections in a Cohort of High-Risk Women Aged 25-65 Years
Rachel L. Winer et al.
JOURNAL OF INFECTIOUS DISEASES (2016)
Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models
Marc Brisson et al.
LANCET PUBLIC HEALTH (2016)
A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women
E. A. Joura et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
ACC/AHA Statement on Cost/Value Methodology in Clinical Practice Guidelines and Performance Measures A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines
Jeffrey L. Anderson et al.
CIRCULATION (2014)
Long-Term Follow-up Observation of the Safety, Immunogenicity, and Effectiveness of GardasilTM in Adult Women
Joaquin Luna et al.
PLOS ONE (2013)
End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age
X. Castellsague et al.
BRITISH JOURNAL OF CANCER (2011)
The accuracy of cancer mortality statistics based on death certificates in the United States
Robert R. German et al.
CANCER EPIDEMIOLOGY (2011)
Human Papillomavirus Infection and Reinfection in Adult Women: the Role of Sexual Activity and Natural Immunity
Helen Trottier et al.
CANCER RESEARCH (2010)
Sequential Acquisition of Human Papillomavirus (HPV) Infection of the Anus and Cervix: The Hawaii HPV Cohort Study
Marc T. Goodman et al.
JOURNAL OF INFECTIOUS DISEASES (2010)
Transmission dynamic modelling of the impact of human papillomavirus vaccination in the United Kingdom
Yoon Hong Choi et al.
VACCINE (2010)
Impact of vaccinating boys and men against HPV in the United States
Elamin H. Elbasha et al.
VACCINE (2010)
Duration and Clearance of Anal Human Papillomavirus (HPV) Infection among Women: The Hawaii HPV Cohort Study
Yurii B. Shvetsov et al.
CLINICAL INFECTIOUS DISEASES (2009)
Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial
Nubia Munoz et al.
LANCET (2009)
Model for assessing human papillomavirus vaccination strategies
Elamin H. Elbasha et al.
EMERGING INFECTIOUS DISEASES (2007)
Discrepancies between clinical and autopsy diagnosis and the value of post mortem histology; a meta-analysis and review
J Roulson et al.
HISTOPATHOLOGY (2005)
Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results
N Muñoz et al.
JOURNAL OF INFECTIOUS DISEASES (2004)
Share Paper
